Autoimmune Hepatitis

Table of Contents

  1. What Is Autoimmune Hepatitis
  2. Types of Autoimmune Hepatitis
  3. Pathogenesis and Triggers
  4. Clinical Presentation
  5. Diagnosis and Criteria
  6. Treatment — Induction
  7. Treatment — Maintenance and Refractory Disease
  8. Complications and Prognosis
  9. AIH in Special Populations
  10. Liver Transplantation
  11. Overlap Syndromes
  12. Research Papers
  13. Connections
  14. Featured Videos

What Is Autoimmune Hepatitis

Autoimmune hepatitis (AIH) is a chronic immune-mediated inflammatory liver disease in which the body's own immune system attacks hepatocytes — the main functional cells of the liver. Unlike viral hepatitis, which is caused by an external pathogen, AIH arises from a loss of self-tolerance: the immune system fails to distinguish liver tissue from foreign invaders and mounts a sustained inflammatory response against it.

At the cellular level, AIH is driven primarily by T-cell-mediated destruction. CD4+ T helper cells and CD8+ cytotoxic T cells infiltrate the liver and attack hepatocytes along the boundary between portal tracts and liver lobules, a pattern called interface hepatitis. This causes progressive liver injury that, if untreated, leads to fibrosis, cirrhosis, and liver failure.

The disease has a characteristic laboratory and clinical fingerprint:

AIH has a bimodal age distribution, with one peak occurring between ages 10 and 30 years and a second peak between ages 50 and 70 years. Women account for 70–80% of all cases, a sex bias typical of many autoimmune diseases. Prevalence estimates in Europe and North America range from 17 to 20 cases per 100,000 population. While AIH can affect people of any ethnicity, certain HLA genotypes increase risk substantially.

Importantly, AIH is a treatable condition. With immunosuppressive therapy, the majority of patients achieve biochemical remission and have a normal life expectancy. The challenge lies in timely diagnosis — many patients present with nonspecific symptoms, and the disease can mimic acute viral hepatitis or be discovered incidentally on routine blood tests.

Back to Table of Contents

Types of Autoimmune Hepatitis

AIH is classified into two main types based on the autoantibody profile. This classification has clinical and prognostic implications, though both types are treated with the same immunosuppressive regimen.

Type 1 AIH

Type 1 is the most common form worldwide, accounting for approximately 80% of all AIH cases. It is defined by the presence of anti-nuclear antibody (ANA) and/or anti-smooth muscle antibody (SMA). The SMA targets F-actin, a cytoskeletal protein. Some patients also carry anti-neutrophil cytoplasmic antibody (ANCA), typically in the perinuclear pattern (pANCA).

Type 1 can occur at any age and is strongly associated with concurrent autoimmune conditions, including:

Patients with Type 1 AIH generally have a favorable response to corticosteroid therapy and achieve long-term remission, though relapse after withdrawal of treatment is common.

Type 2 AIH

Type 2 is less common and occurs predominantly in children and young adults, though it can affect adults. It is defined by the presence of anti-liver kidney microsome type 1 (anti-LKM-1), which targets the cytochrome P450 enzyme CYP2D6. Some patients also carry anti-liver cytosol type 1 (anti-LC1), which targets formiminotransferase cyclodeaminase (FTCD).

Type 2 AIH tends to present more acutely and severely than Type 1. Key features include:

Type 3 (Less Established)

A third category, sometimes labeled Type 3, is defined by anti-soluble liver antigen/liver-pancreas (anti-SLA/LP) antibodies targeting the transfer RNA-associated protein (TRNAU1AP). This subtype shares clinical features with Type 1 AIH but may be associated with more severe disease and a higher risk of relapse. Its status as a distinct type is debated, and many authorities classify it as a serologic variant of Type 1 rather than a separate entity.

Back to Table of Contents

Pathogenesis and Triggers

The underlying cause of AIH involves a complex interplay between genetic predisposition, environmental triggers, and a breakdown in immunologic self-tolerance.

Genetic Susceptibility

HLA (human leukocyte antigen) genes on chromosome 6 are the most important genetic risk factors for AIH. Specific associations include:

Environmental Triggers

In genetically susceptible individuals, various environmental exposures can trigger loss of self-tolerance through molecular mimicry — a process in which microbial or drug antigens resemble self-proteins closely enough that immune responses cross-react with liver tissue. Identified triggers include:

Immune Dysregulation

The central immunologic defect in AIH is a failure of regulatory T cells (Tregs) to suppress autoreactive T cells. Normally, Tregs expressing FOXP3 dampen immune responses to self-antigens. In AIH, Treg numbers and function are reduced, allowing autoreactive CD4+ Th1 and Th17 cells to expand and infiltrate the liver. These cells release pro-inflammatory cytokines (interferon-gamma, IL-17, TNF-alpha) and activate CD8+ cytotoxic T cells and B cells. The result is the characteristic interface hepatitis — dense inflammatory infiltrates rich in plasma cells at the portal-parenchymal boundary — along with hepatocyte destruction and progressive fibrosis.

Back to Table of Contents

Clinical Presentation

AIH presents in several distinct patterns. Recognizing the full spectrum is essential because delayed diagnosis allows progressive liver damage to accumulate silently.

Acute Hepatitis Presentation

Some patients present acutely, with:

This pattern closely mimics acute viral hepatitis, and distinguishing between the two requires careful serologic testing. A particularly severe form — Acute Severe AIH (AS-AIH) — is characterized by coagulopathy (INR ≥1.5) and jaundice, occurring in the absence of cirrhosis. AS-AIH carries a high risk of progression to acute liver failure and has a poor prognosis without rapid treatment or transplantation.

Chronic Insidious Presentation

The most common presentation is a gradual, months-to-years onset with nonspecific symptoms:

A striking finding is that 30–40% of patients already have established cirrhosis at the time of first diagnosis, meaning the disease progressed silently for years before being identified. This underscores the importance of not dismissing mildly elevated liver enzymes.

Incidental Discovery

Many patients are entirely asymptomatic and are diagnosed only because liver function tests were performed for another reason — a pre-employment screen, insurance physical, or workup for fatigue or arthralgia. These patients may have significant underlying liver inflammation or even early fibrosis despite feeling well.

Overlap Syndromes

A subset of patients have features of both AIH and another liver disease simultaneously. The two most recognized overlaps are:

Back to Table of Contents

Diagnosis and Criteria

No single test diagnoses AIH definitively. Diagnosis requires integrating laboratory findings, autoantibody results, liver histology, and exclusion of other causes of hepatitis. Two scoring systems are used: the Simplified IAIHG Criteria (most commonly used in clinical practice) and the more complex Original IAIHG Scoring System (primarily for research).

Simplified IAIHG Criteria (Hennes 2008)

Points are assigned across four domains:

A score of 6 points = probable AIH; a score of ≥7 points = definite AIH.

Key Laboratory Investigations

Liver Biopsy

Liver biopsy is required for the diagnosis of AIH. Characteristic histologic findings include:

Biopsy also stages fibrosis, which guides urgency of treatment and prognosis. Non-invasive fibrosis markers (FIB-4, liver stiffness by elastography) can supplement but do not replace biopsy in AIH.

Back to Table of Contents

Treatment — Induction

AIH is highly responsive to immunosuppression. Early treatment prevents progression to cirrhosis and reduces liver-related mortality. The goal of induction therapy is to rapidly suppress inflammation and bring transaminases and IgG into the normal range.

Standard Regimen: Prednisone Plus Azathioprine

The combination of prednisone and azathioprine is the established first-line treatment worldwide:

With this regimen, 65–80% of patients achieve biochemical remission (ALT and AST within normal limits, normal IgG) within 2 years. Histologic remission (resolution of interface hepatitis on repeat biopsy) lags biochemical remission by 3–6 months.

Budesonide as an Alternative

Budesonide (9 mg/day) is an alternative to prednisone in patients with non-cirrhotic AIH. Its advantage is extensive hepatic first-pass metabolism — approximately 90% is extracted by the liver before reaching systemic circulation — resulting in far fewer corticosteroid side effects (less weight gain, hyperglycemia, osteoporosis, cushingoid features).

A key limitation: budesonide must not be used in patients with cirrhosis. In cirrhotic livers, portal hypertension creates portosystemic shunts that bypass hepatic first-pass metabolism, allowing budesonide to reach systemic circulation at concentrations comparable to prednisone — eliminating its safety advantage.

Monitoring Response

Response to induction therapy is monitored by:

Failure to achieve biochemical response within 4–6 weeks, or worsening despite treatment, should prompt re-evaluation of the diagnosis and consideration of second-line agents.

Back to Table of Contents

Treatment — Maintenance and Refractory Disease

Once biochemical remission is achieved, the goal shifts to maintaining remission with the lowest effective immunosuppressive dose to minimize long-term drug toxicity.

Azathioprine Monotherapy

After remission is established, prednisone is gradually tapered and discontinued. Most patients can be maintained on azathioprine monotherapy at 1.5–2 mg/kg/day. This approach avoids long-term corticosteroid toxicity while maintaining immunosuppressive control.

Before initiating azathioprine, TPMT (thiopurine methyltransferase) genotyping or phenotyping is recommended. TPMT is the key enzyme responsible for azathioprine metabolism. Patients with low or absent TPMT activity (poor metabolizers — approximately 0.3% of the population) are at risk for severe, potentially life-threatening myelosuppression if given standard azathioprine doses. TPMT-poor metabolizers require dose reduction or an alternative agent. Intermediate metabolizers (approximately 10% of the population) may tolerate standard doses with careful monitoring.

6-Mercaptopurine (6-MP) is the active metabolite of azathioprine and can be used as an alternative in patients who are intolerant of azathioprine due to gastrointestinal side effects.

Mycophenolate Mofetil

Mycophenolate mofetil (MMF) at 2 g/day (1 g twice daily) is the most widely used second-line agent for patients who:

MMF inhibits inosine monophosphate dehydrogenase, selectively suppressing lymphocyte proliferation. Response rates in azathioprine-intolerant or refractory patients are approximately 60–80%. MMF is teratogenic and is contraindicated in pregnancy.

Calcineurin Inhibitors

For patients who fail MMF, tacrolimus or cyclosporine — calcineurin inhibitors that block T-cell activation — are third-line options. Both have demonstrated efficacy in small series and case reports. Tacrolimus is generally preferred due to a more favorable side-effect profile. Significant adverse effects include nephrotoxicity, hypertension, and increased infection risk.

Biologic Agents

For truly refractory AIH, several biologics have been used in small series:

None of these are approved specifically for AIH; use is guided by expert consensus and individual patient circumstances.

Drug-Induced AIH

When AIH is triggered by a specific drug (minocycline, nitrofurantoin, checkpoint inhibitors, others), withdrawal of the offending drug is the first step and may be sufficient for resolution. A short course of corticosteroids is added if the patient does not improve promptly or has severe hepatitis. Checkpoint inhibitor-related hepatitis (immune-related adverse event) is managed with prednisone 1–2 mg/kg/day and permanent discontinuation of the checkpoint inhibitor.

Treatment Withdrawal and Relapse

Withdrawal of immunosuppression is attempted only after at least 2 years of complete biochemical and histologic remission (confirmed by repeat biopsy showing no interface hepatitis). Despite this, 50–80% of patients relapse within 3 years of stopping treatment. Because relapse carries risks of hepatic decompensation and accelerated fibrosis, most gastroenterologists and hepatologists recommend lifelong maintenance therapy, particularly for patients with cirrhosis, multiple prior relapses, or Type 2 AIH.

Back to Table of Contents

Complications and Prognosis

With appropriate treatment, the long-term prognosis of AIH is good. Patients who achieve and maintain biochemical remission have a life expectancy comparable to the general population. However, delayed diagnosis, inadequate treatment, or treatment non-adherence can lead to serious complications.

Liver Cirrhosis

Cirrhosis develops in approximately 40% of patients with AIH over the course of the disease, particularly in those with delayed diagnosis or inadequate treatment response. Once cirrhosis is established, the risk of liver-related complications — portal hypertension, varices, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy — increases substantially. Cirrhotic AIH patients require standard cirrhosis monitoring and management protocols.

Hepatocellular Carcinoma (HCC)

HCC can develop in AIH-related cirrhosis. The risk is lower than in hepatitis B or C cirrhosis, but it is not negligible. Annual risk estimates in AIH cirrhosis are approximately 1–2%. Current guidelines recommend HCC surveillance every 6 months using liver ultrasound with or without serum alpha-fetoprotein (AFP) in all patients with AIH-related cirrhosis.

Complications of Immunosuppressive Therapy

Long-term corticosteroid use carries significant morbidity:

Azathioprine carries its own risks:

Overall Prognosis

Without treatment, AIH historically had a 5-year survival of approximately 50%. With current immunosuppressive therapy, remission rates exceed 65% at 2 years, and long-term survival is near normal in patients without established cirrhosis. Patients with cirrhosis at diagnosis have worse outcomes and more frequent decompensation. Acute severe AIH with high MELD score (≥26) carries a poor prognosis without urgent treatment or liver transplantation.

Back to Table of Contents

AIH in Special Populations

Children and Adolescents

AIH in children has several distinctive features compared to adults:

Pregnancy

Pregnancy in women with AIH requires careful management:

Elderly Patients

AIH in older adults (age >60) can present differently:

Acute Liver Failure from AIH

When AIH presents as acute liver failure (coagulopathy + encephalopathy), rapid decision-making is critical:

Back to Table of Contents

Liver Transplantation

Liver transplantation is a life-saving option for patients with AIH who cannot be adequately managed with medical therapy. Outcomes are generally excellent, though AIH can recur in the transplanted organ.

Indications for Transplantation

Post-Transplant Outcomes

Overall, outcomes after liver transplantation for AIH are very good, with 5-year patient survival rates of 80–85%, comparable to transplantation for other indications. However, two important post-transplant phenomena must be recognized:

Immunosuppression After Transplant

Standard post-transplant immunosuppression (tacrolimus ± mycophenolate ± prednisone) is sufficient to prevent both allograft rejection and AIH recurrence in most patients. AIH patients may benefit from indefinite low-dose prednisone as part of their maintenance regimen, unlike many other liver transplant indications where steroids are eventually withdrawn.

Back to Table of Contents

Overlap Syndromes

Overlap syndromes occur when a patient has features of two distinct autoimmune liver diseases simultaneously. These are not rare — estimates suggest overlap features occur in 10–15% of patients with autoimmune liver disease — and they complicate both diagnosis and treatment.

AIH-PBC Overlap

The Paris criteria are the most widely used diagnostic framework for AIH-PBC overlap. A patient must meet at least 2 of 3 criteria for each condition:

Treatment of AIH-PBC overlap uses a combination approach:

AIH-PSC Overlap

AIH-PSC overlap is particularly prevalent in children and young adults with concurrent inflammatory bowel disease (especially ulcerative colitis). It is also called "autoimmune sclerosing cholangitis" in pediatric practice.

Key features:

Management is challenging. Immunosuppression for the hepatitic component and UDCA for the biliary component are used, but the biliary disease often progresses regardless of immunosuppression. Dominant biliary strictures may require endoscopic dilation. The long-term prognosis of AIH-PSC overlap is worse than AIH alone, and many patients progress to biliary cirrhosis requiring transplantation.

Back to Table of Contents

Research Papers

The following PubMed searches provide access to peer-reviewed literature on autoimmune hepatitis.

  1. AIH diagnosis — IAIHG simplified scoring criteria (PubMed search)
  2. Azathioprine and prednisone in AIH — treatment outcomes (PubMed search)
  3. Budesonide in non-cirrhotic AIH — randomized controlled trial (PubMed search)
  4. Mycophenolate mofetil in refractory autoimmune hepatitis (PubMed search)
  5. AIH cirrhosis and HCC surveillance (PubMed search)
  6. AIH in pregnancy — outcomes and postpartum flare (PubMed search)
  7. Drug-induced and checkpoint inhibitor-related autoimmune hepatitis (PubMed search)
  8. AIH-PBC overlap syndrome — Paris criteria and treatment (PubMed search)
  9. AIH relapse after treatment withdrawal (PubMed search)
  10. Pediatric autoimmune hepatitis Type 2 — anti-LKM-1 in children (PubMed search)
  11. TPMT genotyping and azathioprine myelosuppression risk (PubMed search)
  12. Acute severe AIH — MELD score and liver transplant outcomes (PubMed search)

Back to Table of Contents

Connections

Back to Table of Contents